Fresenius Medical Care AG & Co. KGaA

Earnings Release • Sep 6, 2012

Goldman Sachs 9th Annual European Medtech & Healthcare Services Conference

London September 6, 2012

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views with respect to future events an financial performance. Actual results could differ materially from those included in the forwardlooking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forwardlooking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

Financial Results

Excellent revenue growth of 13% in Q2 2012 in constant currency (North America +14%; International +11%)

In US-\$ million	Q2 2011	Q2 2012	Growth in %
Net revenue	3,138	3,428	9
EBIT	510	589	16
Net income attributable to FMC AG & Co. KGaA	261	289	11
Earnings per ordinary share	0.86	0.95	10
Operating cash flow	311	451	45
Excluding investment gain:
Net income attributable to FMC AG & Co. KGaA	261	276	6

Q2 | Revenue split by region

North America

Revenue \$ 2,249 m + 14% Organic growth + 2%

International ~ 34% of total revenue

Revenue	\$ 1,171 m	+	11%cc
Organic growth			+ 6%
EMEA	\$ 725 m		+ 9%cc
Asia-Pacific	\$ 256 m		+ 8%cc
Latin America	\$ 190 m	+	20%cc

2012 | Outlook confirmed | excl. investment gain

Revenue growth in constant currency	• 13 -15%
Revenue	1) • ~ \$ 14.0 bn
Operating margin	• ~ 16.9%
Net income, attributable to shareholders of FMC AG & Co. KGaA	1) • ~ \$ 1.14 bn
Acquisitions	• ~ \$ 1.8 bn
Capex	• ~ \$ 0.7 bn
Total debt / EBITDA	• < 3.0

1) US-GAAP revenue following first time adoption of Accounting Standards Codification 954-605 where patients service revenues is reduced for bad debt. The comparable revenue for the fiscal year 2011 is \$12,571 million. Additionally we are defining the ~ sign as a +/- 0-2% deviation from the respective numbers

Market position by major product groups

	Rank 1	Rank 2
Dialyzers	FME	Gambro
Dialysis machines	FME	Nikkiso
Hemodialysis concentrates	FME	Fuso
Bloodlines	FME	Gambro
Peritoneal dialysis products	Baxter	FME

Dialyzers

Dialysis machines

Sold around 93,000,000 dialyzers in 2011

Global Market Opportunity

Dialysis Market by Region Global Reimbursement for

Market Opportunities for Fresenius Medical Care

Product Launches

CREATING A FUTURE WORTH LIVING. FOR PEOPLE. WORLDWIDE. EVERY DAY.

Thank you very much for your attention!

© Fresenius Medical Care, September 2012 16